CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
增强 CAR-T 细胞疗法抗实体瘤效果：机制与耐药逆转
英文原题：Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
查看英文原题
Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法属于过继性免疫细胞疗法，利用工程化免疫受体增强肿瘤特异性杀伤。迄今为止，新一代CAR-T 细胞疗法显著提升了白血病治疗的有效性和稳健性。然而，目前仅有少数CAR-T 细胞疗法获得FDA批准，且均应用于血液系统恶性肿瘤。通过CAR-T 细胞疗法靶向实体瘤仍面临诸多问题，如肿瘤异质性、抗原丢失、浸润能力不足及免疫抑制微环境。近期进展为CAR-T 细胞疗法耐药机制提供了新见解，并催生了潜在逆转疗法。在本综述中，我们主要介绍CAR-T 细胞治疗实体瘤时存在的障碍，并讨论克服这些挑战的方法。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy, belonging to adoptive immune cells therapy, utilizes engineered immunoreceptors to enhance tumor-specific killing. By now new generations of CAR T-cell therapies dramatically promote the effectiveness and robustness in leukemia cases.
However, only a few CAR T-cell therapies gain FDA approval till now, which are applied to hematologic cancers. Targeting solid tumors through CAR T-cell therapies still faces many problems, such as tumor heterogeneity, antigen loss, infiltration inability and immunosuppressive micro-environment.
Recent advances provide new insights about the mechanisms of CAR T-cell therapy resistance and give rise to potential reversal therapies. In this review, we mainly introduce existing barriers when treating solid tumors with CAR T-cells and discuss the methods to overcome these challenges.
论文信息
- 作者
- Qin Y、Xu G
- 单位
- National Institute of Biological Sciences, Beijing, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36569859 · DOI 10.3389/fimmu.2022.1053120
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →